First Patient Dosed in VIR-5500 T-Cell Engager Trial in Metastatic Prostate Cancer
The first patient has been dosed in a phase 1 trial (NCT05997615) of VIR-5500, a dual‑masked PSMA‑targeting T‑cell engager for metastatic prostate cancer.
The first patient has been dosed in a phase 1 trial (NCT05997615) of VIR-5500, a dual‑masked PSMA‑targeting T‑cell engager for metastatic prostate cancer.
Studies of new immunotherapy agents are significant because they add to the limited treatment options for patients with metastatic prostate cancer, a disease that remains largely incurable and has a poor prognosis.
Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Related signals
- Apalutamide Treatment and Metastasis‑free Survival in Prostate Cancer
- The prostate cancer conundrum revisited: Treatment changes and prostate cancer mortality declines
- The contemporary management of prostate cancer
- Extracellular TROP2 Fragment Identified as a Potential Biomarker and Metastasis Driver
- Overall survival of prostate cancer patients treated with Lu‑177 PSMA 617 (Pluvicto®) in a multidisciplinary setting— a single center experience